AUMED, a.s. completed a clinical trial, phase I, of the medicinal product TFI (Transfer Factor) lyophilized mucoadhesive tablet for buccal-oral administration on 18.11.2024. The new medicinal product is based on the results of AUMED’s own research activities in the field of transfer factors. The purpose of this study was to confirm that no significant safety issues would arise in a small sample of study subjects. No adverse effects were observed in this study. Other measurements, such as laboratory results, vital signs or physical findings, did not indicate any safety concerns that would require special attention.
AUMED has received support for the project titled “Development of an Immunization Product for Protection Against the Causative Agent of…
AUMED has received support for the project “Innovation in the Production of Immunological Preparations,” registration number CZ.01.01.01/02/24_051/0004982. The essence of…
Our subsidiary, AUMED Pharma a.s., is expanding the Phage Glow range with two new product lines: ATOPCARE Atopcare is here…
Research projects of Aumed, a.s. are financed by the European Structural Funds and with financial support from the state budget through the Ministry of Industry and Trade. A complete list of all ongoing and completed projects with this support can be found here.
Ministry of Industry and Trade
Program TRIO
European Union
European Regional Development Fund
OP Enterprise and Innovation for Competitiveness
Tel.: +420 603 587 701
Komořanská 326/63, 143 14 Praha - Modřany, Česká republika
(c) 2017, Aumed a.s
